

Haematologica
HAEMATOL/2015/139089
Version 4

Frontline therapy with high-dose imatinib vs. 2nd generation tyrosine kinase inhibitor in patients with chronic-phase chronic myeloid leukemia
- A propensity score analysis

Koji Sasaki, Hagop Kantarjian, Elias Jabbour, Farhad Ravandi, Koichi Takahashi, Marina Konopleva, Gautam Borthakur, Guillermo Garcia-Manero, William Wierda, Naval Daver, Preetesh Jain, Toshihisa Satta, Sherry Pierce, May Beth Rios, and Jorge E. Cortes

Disclosures: J.C. received research support from Ariad, BMS, Novartis, Pfizer, and Teva, and is a consultant for Ariad, BMS, Novartis and Pfizer. F.R. received research funding from Novartis and BMS. E.J. received consultancy for Ariad, BMS, and Pfizer, and research grants from Ariad, BMS, TEVA, and Pfizer. N.D. received research funding from BMS, Novartis, Sunesis, Incyte, and Bioline. H.K. received research grants from Novartis, BMS, Pfizer, and Ariad. Other authors have nothing to disclose.

Contributions: K.S. treated the patients, collected data, designed the study, analyzed the data, and wrote the manuscript. J.C. treated the patients, designed the study, analyzed the data and edited the manuscript. S.P. and M.R. managed the data. P.J. and T.S. treated the patient and collected the data. S.O., E.J., F.R., M.K., K.T., G.B., N.P., N.D., H.K. treated the patients. All authors provided significant intellectual input, and reviewed and approved the final version of the manuscript.